BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9628654)

  • 21. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
    Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
    Karr JF; Kantor JA; Hand PH; Eggensperger DL; Schlom J
    Cancer Res; 1995 Jun; 55(11):2455-62. PubMed ID: 7538903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcription-targeted gene therapy for androgen-independent prostate cancer.
    Martiniello-Wilks R; Tsatralis T; Russell P; Brookes DE; Zandvliet D; Lockett LJ; Both GW; Molloy PL; Russell PJ
    Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical application for gene therapy in prostate cancer].
    Gotoh A; Kamidono S; Chung LW
    Hinyokika Kiyo; 1997 Nov; 43(11):829-33. PubMed ID: 9436031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
    Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of proliferation and expression of AR/PSA by herbal supplement Equiguard in LNCaP cells cultured in androgen-proficient FBS and androgen-deficient charcoal-stripped FBS is correlated with increased serine-15 phosphorylation of the tumor suppressor gene p53.
    Lu X; Guo J; Hsieh TC; Wu JM
    Anticancer Res; 2003; 23(3B):2489-98. PubMed ID: 12894532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
    Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
    Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer.
    Kijima T; Osaki T; Nishino K; Kumagai T; Funakoshi T; Goto H; Tachibana I; Tanio Y; Kishimoto T
    Cancer Res; 1999 Oct; 59(19):4906-11. PubMed ID: 10519403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
    Tsui KH; Feng TH; Chung LC; Chao CH; Chang PL; Juang HH
    Anticancer Res; 2008; 28(4A):1969-76. PubMed ID: 18649734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
    Yu DC; Sakamoto GT; Henderson DR
    Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer.
    Hall SJ; Mutchnik SE; Yang G; Timme TL; Nasu Y; Bangma CH; Woo SL; Shaker M; Thompson TC
    Cancer Gene Ther; 1999; 6(1):54-63. PubMed ID: 10078964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
    Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
    Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
    Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
    Trofimova I; Dimtchev A; Jung M; Rosenthal D; Smulson M; Dritschilo A; Soldatenkov V
    Cancer Res; 2002 Dec; 62(23):6879-83. PubMed ID: 12460902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
    Shibahara T; Onishi T; Franco OE; Arima K; Nishikawa K; Yanagawa M; Hioki T; Watanabe M; Hirokawa Y; Shiraishi T; Sugimura Y
    Anticancer Res; 2006; 26(5A):3365-71. PubMed ID: 17094454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
    Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
    Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.